What are the definition, relevant anatomy and physiology, etiology and pathophysiology, signs and symptoms, typical cardiovascular intensive care unit (CVICU) presentation, diagnostic evaluation, medical and nursing interventions, immediate nursing priorities, potential complications, red‑flag findings, CVICU management tips, expected clinical course, and prognostic indicators for posterior ST‑segment elevation myocardial infarction (STEMI)?

Posterior STEMI

Definition

Posterior STEMI is an ST-segment elevation myocardial infarction involving the posterior (inferobasal) wall of the left ventricle, most commonly caused by occlusion of the left circumflex artery or posterior descending artery, and should be managed as a STEMI equivalent requiring immediate reperfusion therapy. 1

• Posterior MI represents 15-21% of all acute myocardial infarctions, with the vast majority occurring in conjunction with inferior or lateral wall involvement 1
• True isolated posterior MI is uncommon, with an incidence of 3-7% of acute coronary syndromes, occurring predominantly in men (72% vs 28% in women) 2
• The posterior wall is not directly faced by any of the standard 12-lead ECG leads, making diagnosis challenging and often resulting in missed or delayed recognition 3

Relevant Anatomy and Physiology

The posterior wall of the left ventricle is supplied primarily by the left circumflex artery (approximately 60% of cases) or the posterior descending artery from the right coronary system. 4

• The posterior wall corresponds to the inferobasal portion of the left ventricle, often within the left circumflex territory 1
• Standard precordial leads V1-V3 face the anterior wall and septum; the posterior wall lies directly opposite, creating "mirror image" ECG changes 1
• Posterior leads V7-V9 are positioned on the left posterior chest wall and directly face the posterior myocardium, allowing direct visualization of ST elevation in this territory 1

Etiology and Pathophysiology

Posterior STEMI results from acute thrombotic occlusion of the left circumflex artery or posterior descending artery following atherosclerotic plaque rupture, leading to transmural ischemia and myocardial necrosis. 5

• The pathophysiologic sequence begins with coronary plaque rupture, followed by platelet aggregation, thrombus formation, and complete vessel occlusion 5
• Risk factors include atherosclerosis, hypertension, diabetes, hyperlipidemia, and smoking 5
• Patients with posterior MI tend to be older (mean age 64 years vs 59 years) with more cardiovascular risk factors compared to those with other MI locations 6
• The size and location of infarction depend on the site of occlusion, presence of collateral circulation, and time to reperfusion 1

Signs & Symptoms

Patients present with typical ischemic chest pain lasting >10-20 minutes that does not fully respond to nitroglycerin, though presentations may be atypical, especially in elderly patients. 1

• Chest pain/discomfort is the cardinal symptom, often with radiation to the neck, lower jaw, or left arm 1
• Other locations include epigastric or interscapular pain 1
• Elderly patients commonly present with atypical symptoms: fatigue, dyspnea, faintness, or syncope 1
• Physical examination may reveal pallor, sweating, hypotension or narrow pulse pressure, pulse irregularities, bradycardia or tachycardia, third heart sound (S3), and basal rales 1
• Autonomic nervous system activation is common, manifesting as sympathetic (tachycardia, hypertension) or parasympathetic (bradycardia, hypotension) predominance 1

Typical CVICU Presentation

Posterior STEMI patients in the CVICU typically present post-catheterization after primary PCI of the circumflex or posterior descending artery, requiring hemodynamic monitoring and surveillance for complications including heart failure, arrhythmias, and reinfarction. 6, 3

• Patients with posterior MI have larger infarct size (evidenced by higher peak creatine kinase levels) and lower left ventricular ejection fraction at discharge compared to isolated inferior MI 3
• Higher incidence of posterolateral wall motion abnormalities on imaging 3
• Increased risk of adverse clinical events including reinfarction, heart failure, or death 6, 3
• May present with Killip Class ≥2 (signs of heart failure), which indicates high-risk status 7
• Hemodynamic instability, cardiogenic shock, or persistent chest pain despite optimal medical therapy are concerning features 4

Diagnosis & Evaluation

Electrocardiographic Diagnosis

The hallmark ECG finding is ST-segment depression ≥0.5 mm in leads V1-V3 with horizontal morphology and upright terminal T-waves (representing the "mirror image" of posterior ST elevation), which must be confirmed by ST-segment elevation ≥0.5 mm in posterior leads V7-V9. 1

• Standard 12-lead ECG shows isolated ST-segment depression in V1-V3 as the dominant finding, which is an ST-segment elevation equivalent 1
• Horizontal ST-segment depression with upright precordial T-waves in V1-V3 distinguishes posterior MI from anterior non-STEMI (which shows downsloping ST depression with T-wave inversion) 1
• Obtain posterior leads V7-V9 immediately in any patient with ST depression in V1-V3 and ongoing ischemic symptoms 1, 4
• ST elevation ≥0.5 mm in leads V7-V9 confirms posterior STEMI and mandates reperfusion therapy 1
• Tall R waves in V1-V2 may develop but are present in only 26% of cases and should not be relied upon for diagnosis 6
• Approximately 4% of acute MI patients have ST elevation isolated to posterior leads that is "hidden" from standard 12-lead ECG 8, 7

Serial ECG Monitoring

Repeat ECGs every 10-15 minutes to capture evolving ST changes, as early presentations may show only hyperacute T-waves or minimal ST deviation. 4

• Some patients present very early with hyperacute T-waves preceding ST-segment elevation 1
• Dynamic ST-segment changes on serial ECGs support the diagnosis of acute coronary occlusion 1
• Transient ST elevation may indicate Prinzmetal's angina or early ACS presentation 8, 7

Cardiac Biomarkers

Measure high-sensitivity cardiac troponin immediately and repeat at 6-12 hours; troponin elevation confirms myocardial necrosis and guides invasive strategy timing. 4, 7

• Do not wait for troponin results to initiate reperfusion treatment in patients with diagnostic ECG findings 1
• Troponin-positive patients require invasive strategy within 24-72 hours if not already treated with primary PCI 4, 7
• Peak creatine kinase levels are higher in posterior MI, reflecting larger infarct size 3

Imaging

Perform urgent echocardiography to identify posterolateral wall motion abnormalities, assess left ventricular ejection fraction, and exclude alternative diagnoses. 1, 4

• Echocardiography can detect regional wall motion abnormalities within minutes of coronary occlusion 4
• Posterolateral wall hypokinesis or akinesis confirms posterior involvement 3
• Absence of wall motion abnormalities makes major MI unlikely, though findings are not specific 4
• Radionuclide ventriculography demonstrates posterolateral wall motion abnormalities and reduced LVEF 3

Coronary Angiography

Emergency coronary angiography is the definitive diagnostic test and therapeutic intervention, revealing total or critical occlusion of the left circumflex artery in the majority of isolated posterior STEMI cases. 2

• Left circumflex occlusion is the culprit vessel in approximately 60% of posterior MI cases 4
• Posterior descending artery occlusion accounts for remaining cases 4
• Angiography should not be delayed in patients with ongoing ischemic symptoms even if ECG findings are atypical 4

Interventions/Treatments: Medical and Nursing Management

Immediate Reperfusion Therapy

Posterior STEMI with ST elevation ≥0.5 mm in leads V7-V9 should be managed as a STEMI equivalent with immediate primary percutaneous coronary intervention (PCI), targeting door-to-balloon time <90 minutes. 1, 4

• Primary PCI is the preferred reperfusion strategy over fibrinolytic therapy 5
• Patients with posterior MI benefit significantly from successful reperfusion, with improved LVEF at discharge when the infarct-related artery is patent 3
• Do not postpone emergency angiography in patients with ongoing chest pain despite non-diagnostic standard ECG 4
• Suspicion of ongoing myocardial ischemia is an indication for primary PCI strategy even without diagnostic ST-segment elevation on standard 12-lead ECG 1

Fibrinolytic Therapy (When PCI Unavailable)

If primary PCI is not available within 120 minutes of first medical contact, fibrinolytic therapy is indicated for posterior STEMI with ST elevation in V7-V9 and symptom onset <12 hours. 1

• ACC/AHA guidelines classify posterior MI with ST depression in V1-V3 and upright T-waves as a Class II indication for fibrinolytic therapy 1
• Patients with horizontal ST-segment depression and upright precordial T-waves in V1-V3 should be considered eligible for fibrinolytic therapy 1
• Fibrinolytic therapy should NOT be used routinely in patients with ST-segment depression unless posterior MI is suspected, as mortality may increase in other ST-depression subgroups 1

Antiplatelet Therapy

Initiate dual antiplatelet therapy immediately with aspirin plus a P2Y12 inhibitor (ticagrelor, prasugrel, or clopidogrel). 4, 7

• Aspirin should be given as soon as possible 7
• P2Y12 inhibitors (ticagrelor or prasugrel preferred over clopidogrel) should be administered before or at time of PCI 4
• Morphine use is associated with slower uptake and delayed onset of oral antiplatelet agents, potentially leading to early treatment failure 1

Anticoagulation

Administer parenteral anticoagulation (unfractionated heparin, enoxaparin, or bivalirudin) in conjunction with antiplatelet therapy. 7

• Anticoagulation should be initiated immediately and continued through PCI 7

Pain Management

Administer titrated intravenous opioids (morphine 4-8 mg with additional 2 mg doses at 5-15 minute intervals) to relieve pain, which is associated with sympathetic activation and increased cardiac workload. 1

• Pain relief is paramount not only for comfort but to reduce sympathetic-mediated vasoconstriction and cardiac workload 1
• Antiemetics (metoclopramide 5-10 mg IV) may be administered concurrently 1
• Side effects include nausea/vomiting, hypotension with bradycardia, and respiratory depression 1
• Hypotension and bradycardia respond to atropine 0.5-1 mg IV (up to 2 mg total) 1
• NSAIDs should NOT be given for pain relief due to prothrombotic effects 1

Oxygen Therapy

Administer oxygen (2-4 L/min by mask or nasal prongs) only to patients with hypoxemia (SaO2 <90% or PaO2 <60 mmHg), breathlessness, heart failure, or shock. 1

• Routine oxygen is NOT recommended in patients with SaO2 ≥90%, as hyperoxia may increase myocardial injury 1
• Non-invasive monitoring of blood oxygen saturation guides oxygen administration decisions 1

Anxiety Management

Consider a mild tranquilizer (benzodiazepine) in very anxious patients, along with reassurance of the patient and family. 1

• Anxiety is a natural response to MI and surrounding circumstances 1
• Reassurance is of great importance for both patient and family 1

Adjunctive Medical Therapy

Initiate standard post-MI medical therapy including statin, ACE inhibitor or ARB, and beta-blocker (unless contraindicated). 7

• Statins reduce recurrent events and mortality 7
• ACE inhibitors improve remodeling and reduce mortality, especially in patients with reduced LVEF 7
• Beta-blockers reduce mortality and recurrent MI 7

Immediate Nursing Priorities

Continuous ECG Monitoring

Initiate continuous ECG monitoring immediately to detect life-threatening arrhythmias and allow prompt defibrillation. 1

• Monitor for ventricular tachycardia, ventricular fibrillation, complete heart block, and other arrhythmias 4
• Have defibrillator immediately available at bedside 1

Hemodynamic Monitoring

Establish continuous blood pressure monitoring and assess for signs of cardiogenic shock or heart failure. 1, 4

• Monitor for hypotension (systolic BP <100 mmHg), tachycardia (HR >100 bpm), narrow pulse pressure 1, 7
• Assess for signs of heart failure: dyspnea, basal rales, S3 gallop, elevated jugular venous pressure 1
• Killip Class ≥2 indicates high-risk status requiring intensive monitoring 7

Intravenous Access and Medication Administration

Establish reliable IV access for medication administration; avoid intramuscular injections. 1

• Intramuscular injections should be avoided due to interference with cardiac biomarkers and bleeding risk with anticoagulation 1
• Ensure timely administration of antiplatelet agents, anticoagulation, and analgesics 1

Serial ECG Acquisition

Obtain serial 12-lead ECGs with posterior leads V7-V9 every 10-15 minutes to monitor for evolving changes. 4

• Compare current ECGs with previous recordings when available 1
• Document resolution or progression of ST-segment changes 4

Symptom Assessment

Continuously assess chest pain severity using standardized pain scale; report persistent or recurrent pain immediately. 4

• Persistent chest pain despite optimal medical therapy mandates urgent angiography 4
• Recurrent chest pain may indicate reinfarction or failed reperfusion 1

Preparation for Emergency Catheterization

Facilitate rapid transfer to catheterization laboratory; ensure patient NPO status and obtain informed consent. 4

• Target door-to-balloon time <90 minutes for primary PCI 4
• Coordinate with catheterization laboratory team for immediate availability 1

Potential Complications

Heart Failure and Cardiogenic Shock

Posterior MI patients have larger infarct size and lower LVEF, predisposing to heart failure and cardiogenic shock. 6, 3

• Posterolateral wall involvement results in significant myocardium at risk 3
• Monitor for Killip Class progression: Class II (rales, S3), Class III (pulmonary edema), Class IV (cardiogenic shock) 7
• Reduced LVEF <35% indicates high-risk status 7

Arrhythmias

Monitor for life-threatening ventricular arrhythmias, complete heart block, and atrial fibrillation. 4

• Ventricular tachycardia and ventricular fibrillation are common causes of sudden cardiac death in acute MI 1
• Complete heart block may occur, particularly with concomitant inferior wall involvement 4
• Have temporary pacing capability available 4

Reinfarction

Posterior MI patients have higher incidence of reinfarction compared to other MI locations. 6, 3

• Monitor for recurrent chest pain and new ECG changes 3
• Reinfarction significantly worsens prognosis 3

Mechanical Complications

Although less common with posterior MI, monitor for papillary muscle rupture (causing acute mitral regurgitation), ventricular septal rupture, and free wall rupture. 5

• New systolic murmur warrants immediate echocardiography 5
• Sudden hemodynamic deterioration may indicate mechanical complication 5

Pericarditis

Post-MI pericarditis may develop 1-3 days after infarction. 5

• Presents with positional chest pain and pericardial friction rub 5
• Treat with aspirin or NSAIDs (though NSAIDs should be used cautiously in acute phase) 5

Relevant Red Flags & CVICU Tips

Critical Diagnostic Pitfalls

Never dismiss ST-segment depression in V1-V3 as "non-specific" or "anterior ischemia" without obtaining posterior leads V7-V9, as this represents the most common missed diagnosis in posterior STEMI. 1, 4

• Approximately 10.9% of patients without ST elevation in standard ECG leads have ST elevation in posterior leads 6
• Failure to obtain posterior leads results in denial of reperfusion therapy, larger infarction, and worse outcomes 1
• The comprehensive and routine application of posterior leads is crucial in patients with subtle ST-segment changes who do not fulfill standard STEMI criteria 2

ECG Interpretation Pearls

Horizontal ST-segment depression with upright T-waves in V1-V3 is the key pattern distinguishing posterior STEMI from anterior non-STEMI (which shows downsloping ST depression with T-wave inversion). 1

• This pattern represents the "mirror image" of posterior ST elevation 1
• Always obtain V7-V9 leads when this pattern is present 1

Medication Cautions

Do NOT administer nitrates or diuretics before confirming absence of right ventricular involvement, as concomitant RV infarction (present in some inferior-posterior MIs) causes profound hypotension with these agents. 4, 7

• Obtain right-sided leads (V3R-V4R) in all patients with inferior or posterior MI 1
• ST elevation ≥1 mm in V4R indicates RV involvement requiring preload maintenance 4, 7

Morphine and Antiplatelet Interaction

Be aware that morphine delays absorption and reduces effectiveness of oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel), potentially leading to early treatment failure. 1

• This interaction is unavoidable but important to recognize 1
• Consider more potent parenteral antiplatelet agents in patients requiring high-dose opioids 1

Atypical Presentations Requiring High Suspicion

Maintain high suspicion for posterior MI in patients with ongoing ischemic symptoms despite non-diagnostic standard ECG, particularly in elderly patients with atypical presentations. 1

• 1-6% of patients with normal or minimally abnormal ECGs are ultimately diagnosed with NSTEMI or STEMI 7
• Elderly patients commonly present with dyspnea, fatigue, or syncope rather than chest pain 1
• Suspicion of ongoing myocardial ischemia alone justifies urgent coronary evaluation 4

Circumflex Occlusion Recognition

Acute occlusion of the circumflex coronary artery frequently presents without ST-segment elevation on standard 12-lead ECG and may be denied reperfusion therapy, resulting in larger infarction and worse outcomes. 1

• Circumflex occlusion is the culprit in approximately 60% of posterior MI cases 4
• These patients may present with isolated ST depression or even normal standard ECG 1
• Extending standard 12-lead ECG with V7-V9 leads identifies these patients 1

Expected Course and Prognostic Clues

In-Hospital Course

Posterior STEMI patients experience more frequent in-hospital complications compared to other MI locations, including higher rates of heart failure, reinfarction, and death. 6, 3

• In-hospital complications are significantly more frequent (Mantel-Haenszel odds ratio = 7) 6
• Trend toward increased in-hospital mortality, though not always reaching statistical significance in smaller studies 6
• Higher incidence of adverse clinical events (reinfarction, heart failure, or death) compared to isolated inferior MI 3

Impact of Successful Reperfusion

Successful reperfusion (patent infarct-related artery) results in significantly improved LVEF at discharge in posterior MI patients, whereas LVEF remains unchanged without successful reperfusion. 3

• Patency of the infarct-related artery is crucial for myocardial salvage 3
• Posterior MI patients benefit more from thrombolytic therapy compared to other MI locations due to larger amount of myocardium at risk 3
• Time to reperfusion is critical—earlier reperfusion yields better outcomes 5

Prognostic Indicators

Poor prognostic indicators include: larger infarct size (higher peak CK), lower LVEF at discharge, Killip Class ≥2, ST elevation in V7-V9 indicating larger posterior involvement, and failed reperfusion. 7, 6, 3

• Peak creatine kinase levels correlate with infarct size and prognosis 3
• LVEF <35% indicates high-risk status with increased mortality 7
• Presence of heart failure signs (Killip Class ≥2) significantly worsens prognosis 7
• ST elevation in posterior leads V7-V9 identifies patients with larger MI and concomitant posterolateral involvement 3

Long-Term Outcomes

Posterior MI patients require aggressive secondary prevention with optimal medical therapy, cardiac rehabilitation, and close follow-up due to increased risk of recurrent events. 7

• Continuation of dual antiplatelet therapy, statin, ACE inhibitor/ARB, and beta-blocker improves long-term outcomes 7
• Cardiac rehabilitation reduces mortality and improves quality of life 5
• Regular follow-up with echocardiographic assessment of LVEF guides therapy adjustments 5